Novo Nordisk A/S $NVO Shares Sold by Beacon Pointe Advisors LLC

Beacon Pointe Advisors LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 67.5% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,698 shares of the company’s stock after selling 86,461 shares during the period. Beacon Pointe Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,878,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Stone House Investment Management LLC acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at approximately $30,000. NewSquare Capital LLC boosted its position in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares during the period. Disciplina Capital Management LLC grew its holdings in Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares in the last quarter. Dagco Inc. acquired a new stake in Novo Nordisk A/S in the 1st quarter valued at approximately $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at approximately $37,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 0.9%

Shares of NYSE:NVO opened at $47.99 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The stock has a market capitalization of $214.28 billion, a price-to-earnings ratio of 13.95 and a beta of 0.67. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $112.52. The company has a 50 day moving average price of $51.94 and a 200 day moving average price of $59.25.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.25. The company had revenue of $11.79 billion for the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of analyst reports. The Goldman Sachs Group reduced their price target on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, November 28th. Morgan Stanley restated an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating for the company in a research report on Tuesday, November 25th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. Finally, Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $56.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.